Neulasta (pegfilgrastim)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- November 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Summary View

 

Sections Modified

PRECAUTIONS

• Pediatric Use
  • Initial Paragraph (new)
    • The safety and pharmacokinetics of Neulasta were studied in 37 pediatric patients with sarcoma...

 

Nov 2008 label not available on this site